Intravenous thrombolysis for stroke in patients taking non-VKA oral anticoagulants: an update

• References

• 1 Jauch EC, Saver JL, Adams Jr HP. et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2013; 44: 870-947.
• 2 De Smedt A, De Raedt S, Nieboer K. et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 2010; 30: 533-534.
• 3 Inaishi J, Nogawa S, Mano Y. et al. Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature. Rinsho Shinkeigaku 2014; 54: 238-240.
• 4 Matute MC, Guillán M, García-Caldentey J. et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011; 106: 178-179.
• 5 Casado Naranjo I, Portilla-Cuenca JC, Jiménez Caballero PE. et al. Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran. Cerebrovasc Dis 2011; 32: 614-615.
• 6 Sangha N, El Khoury R, Misra V. et al. Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization. J Stroke Cerebrovasc Dis 2012; 21: 917.e5-8.
• 7 Marrone LC, Marrone AC. Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report. Cerebrovasc Dis 2012; 34: 246-247.
• 8 Lee VH, Conners JJ, Prabhakaran S. Intravenous thrombolysis in a stroke patient taking dabigatran. J Stroke Cerebrovasc Dis 2012; 21: 916.e11-2.
• 9 Pfeilschifter W, Abruscato M, Hövelmann S. et al. Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases.ase. Rep Neurol 2013; 05: 56-61.
• 10 Jayathissa S, Gommans J, Harper P. Stroke thrombolysis in patients taking dabigatran. Intern Med J 2013; 43: 826-828.
• 11 Breuer L, Ringwald J, Schwab S. et al. Ischemic stroke in an obese patient receiving dabigatran. N Engl J Med 2013; 368: 2440-2442.
• 12 Kate M, Szkotak A, Witt A. et al. Proposed Approach to Thrombolysis in Dabigatran-Treated Patients Presenting with Ischemic Stroke. J Stroke Cerebrovasc Dis 2014; 23: 1351-1355.
• 13 Diogo C, Nzwalo H, Sobral S. et al. Good outcome after intravenous thrombolysis for acute stroke in a patient under treatment with dabigatran. Am J Emerg Med 2014; 32: 1435.e1-2.
• 14 Tabata E, Yasaka M, Wakugawa Y. et al. Recombinant tissue-type plasminogen activator (rt-PA) therapy in an acute stroke patient taking dabigatran etexilate: a case report and literature review. Intern Med 2014; 53: 1515-1517.
• 15 Govindarajan R, Galvez N. Is intravenous recombinant tissue plasminogen activator (r-tPA) safe in patients on Dabigatran?. J Vasc Interv Neurol 2014; 07: 21-22.
• 16 Staikov I, Mihnev N. Intravenous Thrombolytic Treatment of Acute Ischemic Stroke in Patient on Dabigatran. Am J Neuroprotect Neuroregen 2014; 06: 69-72.
• 17 Fluri F, Heinen F, Kleinschnitz C. Intravenous thrombolysis in a stroke patient receiving rivaroxaban. Cerebrovasc Dis Extra 2013; 03: 153-155.
• 18 Kawiorski MM, Alonso-Canovas A, de Felipe Mimbrera A. et al. Successful intravenous thrombolysis in acute ischaemic stroke in a patient on rivaroxaban treatment. Thromb Haemost 2014; 111: 557-558.
• 19 Seiffge DJ, Traenka C, Gensicke H. et al. Intravenous thrombolysis in stroke patients receiving rivaroxaban. Eur J Neurol 2014; 21: e3-e4.
• 20 Van Hooff RJ, Nieboer K, De Smedt A. et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban. Clin Neurol Neurosurg 2014; 122: 133-134.
• 21 Bornkamm K, Harloff A. Safe intravenous thrombolysis in acute stroke despite treatment with rivaroxaban. J Clin Neurosci 2014; 21: 2012-2013.
• 22 Ishihara H, Torii H, Imoto H. et al. Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Rivaroxaban. J Stroke Cerebrovasc Dis 2014; 23: e457-459.
• 23 Neal AJ, Campbell BC, Chandratheva A. et al. Intravenous thrombolysis for acute ischaemic stroke in the setting of rivaroxaban use. J Clin Neurosci 2014; 21: 2013-2015.
• 24 De Smedt A, Cambron M, Nieboer K. et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with apixaban. Int J Stroke 2014; 09: E31.
• 25 Kimura S, Ogata T, Fukae J. et al. Revascularization for acute ischemic stroke is safe for rivaroxaban users. J Stroke Cerebrovasc Dis 2014; 23: e427-431.
• 26 Korya D, Dababneh H, Moussavi M. et al. Intravenous thrombolysis in a patient using factor Xa inhibitor. J Vasc Interv Neurol 2014; 07: 1-4.
• 27 Xian Y, Liang L, Smith EE. et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. J Am Med Assoc 2012; 307: 2600-2608.
• 28 Steiner T, Böhm M, Dichgans M. et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102: 399-412.
• 29 Hawes EM, Deal AM, Funk-Adcock D. et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost 2013; 11: 1493-1502.
• 30 McGrath ER, Eikelboom JW, Kapral MK. et al. Novel oral anticoagulants: a focused review for stroke physicians. Int J Stroke 2014; 09: 71-78.